June 2026 Research Update

Studies this month added practical, real-world information about complement-blocking medicines for aHUS, including an eculizumab biosimilar and the longer-acting drug ravulizumab. Across these reports, platelet counts usually returned to normal and new thrombotic microangiopathy (TMA) episodes were uncommon during follow-up, but kidney function improvement was less consistent and often only partial. [1] [2] [3]

In a prospective observational study of 50 people (including children and adults) treated with the eculizumab biosimilar Elizaria, most patients reached normal platelet counts and most had no new TMA events during follow-up out to 56 weeks. Kidney filtering (eGFR) improved by a clearly noticeable amount in a minority of patients by week 52, which fits with the idea that stopping blood cell damage and fully recovering kidney function do not always move together. Safety reports in this study described adverse events, with the authors characterizing them as not related to the medicine and noting low immunogenicity. [1]

Two case reports added context about how complement blockade may be used in specific life situations. One pregnancy-associated aHUS case described severe kidney injury requiring dialysis, followed by dialysis independence and partial kidney recovery after starting eculizumab and then switching to ravulizumab, even though treatment began weeks after onset. Another report described a person with aHUS and a new CFH gene variant who started ravulizumab months after onset to prevent relapse, with no TMA recurrence reported during follow-up. [2] [3]

A systematic review and meta-analysis also looked at what happens when eculizumab is discontinued, but the provided summary did not include results. This means June's inputs show that researchers are still trying to clarify how stopping therapy plays out, but this month does not add a clear answer from that review. [4]

For patients, this month mainly adds reassurance about what has been observed in routine care: complement blockade (including a biosimilar form of eculizumab) commonly aligns with stabilization of blood markers and fewer new TMA episodes over about a year of follow-up, while kidney recovery may lag or remain incomplete. The strongest new evidence here is observational rather than a randomized trial, and the individual case reports show what happened for single people rather than what will happen for most. An open question that remains from this month is what the balance of benefits and risks looks like when eculizumab is stopped, because the review was described but outcomes were not provided. [1] [2] [3] [4]

This month made it clearer that aHUS is not one single condition under the hood: different genetic changes and immune antibodies can sit behind a similar-looking TMA crisis, and these differences can relate to relapse patterns and kidney outcomes. The new studies point to three drivers that can matter in real patients: a specific C3 gene variant in a national cohort, a newly characterized CF I (complement factor I) splicing variant that lowers a key protective protein, and anti-CFH (complement factor H) antibodies found in a subset of adults with complement-mediated TMA. [5] [6] [7]

In 37 Dutch patients with the C3 p.Arg161Trp variant, relapse in the native kidneys was common in both children and adults. Early outcomes differed by age group, with children more often having full recovery and adults more often developing severe kidney failure within the first year, and adult recovery was reported more often among those who received eculizumab than among those who did not. This helps put numbers behind a patient question that comes up often: relapse risk can remain high even when many people eventually stabilize, and kidney outcomes can vary by age and treatment era. [5]

A separate genetic and lab-based study focused on a CF I intronic variant (c.328+42G>A) that changes how RNA is spliced, leading to near-complete loss of factor I protein production in patient-derived cells. The authors also reported that carriers of this variant were enriched in a clinically diagnosed aHUS group, suggesting it can contribute to disease risk even in people with one affected copy. This adds a concrete example of how some aHUS-related variants may not be obvious without careful genetic analysis, because the change sits outside the usual protein-coding regions. [6]

An observational study in Chinese adults with complement-mediated TMA found anti-CFH autoantibodies in about 9% of patients, most often targeting one area of factor H (SCRs 15-20). Antibody levels changed between acute illness and remission in their measurements, and many of these antibody-positive patients had severe kidney involvement, with many requiring dialysis at onset and several progressing to kidney failure during follow-up. This helps clarify that, for some people, the immune system itself (not only inherited DNA variants) may be part of why complement regulation breaks down. [7]

For patients and caregivers, these studies mainly matter as better explanation, not as immediate changes in care. They reinforce that relapse risk can be high in certain genetic forms of aHUS, and they show two additional biological pathways that may be checked in specialized settings: hidden splicing variants that reduce protective complement proteins, and anti-CFH antibodies that may be present in a minority of adults with complement-mediated TMA. What remains uncertain from this month is how often these findings should change day-to-day decisions, because some evidence comes from small numbers or single-center cohorts and is still being confirmed across wider populations. [5] [6] [7]

This month also added perspective on why TMA episodes can start and what early signals relate to outcomes. In a broader adult TMA group, worse kidney injury at diagnosis went along with a higher chance of later kidney failure or death, while early improvement during the first week went along with better outcomes. Case reports then illustrated how different triggers (like pancreatitis or anti-GBM disease) can coincide with complement-mediated TMA, with recovery patterns that may depend on the underlying trigger and what can be tolerated. [8] [9] [10]

In a single-center study of 46 adults with biopsy-proven TMA, about 44% progressed to end-stage kidney disease or death during follow-up. People with acute kidney injury and lower baseline kidney filtering at diagnosis had poorer outcomes, while an early treatment response within the first week was linked to better outcomes even after accounting for other factors. The study also found complement gene variants in some tested patients, keeping complement dysregulation on the list of possible underlying drivers in TMA. [8]

One case report described a person who developed aHUS shortly after alcohol-induced pancreatitis and pneumonia, with blood markers and kidney function returning toward baseline using supportive care directed at the pancreatitis rather than plasma exchange or complement inhibition. This single case highlights that, in some situations, a TMA picture can be short-lived and improve as a triggering illness settles, though it does not show what is typical for aHUS more broadly. [9]

Another case report involved anti-GBM disease complicated by secondary complement-mediated TMA in a patient who could not tolerate plasma exchange. Anti-GBM antibody levels fell and lab measures stabilized after protein A immunoadsorption (an antibody-removal procedure) combined with short-term eculizumab, but a single case cannot prove which part of therapy drove the improvement. This adds a real example of how treatment constraints can shape what is tried when TMA overlaps with another immune kidney disease. [10]

For patients, the main value here is understanding prognosis and context during a TMA crisis rather than learning about a new standard approach. The biopsy-proven TMA study suggests that how the kidneys are doing at diagnosis, and whether there is early improvement within about a week, may relate to longer-term outcomes, which may help families make sense of why clinicians watch early trends closely. The case reports remind readers that some TMA episodes happen alongside clear triggers like pancreatitis or anti-GBM disease and may follow a different course than inherited aHUS, but single-patient stories cannot predict what will happen for others. [8] [9] [10]